WO2011009757A3 - Utilisation de bêta-défensine humaine pour influencer le processus de pigmentation naturel - Google Patents

Utilisation de bêta-défensine humaine pour influencer le processus de pigmentation naturel Download PDF

Info

Publication number
WO2011009757A3
WO2011009757A3 PCT/EP2010/060026 EP2010060026W WO2011009757A3 WO 2011009757 A3 WO2011009757 A3 WO 2011009757A3 EP 2010060026 W EP2010060026 W EP 2010060026W WO 2011009757 A3 WO2011009757 A3 WO 2011009757A3
Authority
WO
WIPO (PCT)
Prior art keywords
defensin
influence
human beta
pigmentation process
natural pigmentation
Prior art date
Application number
PCT/EP2010/060026
Other languages
German (de)
English (en)
Other versions
WO2011009757A2 (fr
Inventor
Melanie Giesen
Sabine GRÜDL
Guido Fuhrmann
Original Assignee
Henkel Ag & Co. Kgaa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Henkel Ag & Co. Kgaa filed Critical Henkel Ag & Co. Kgaa
Publication of WO2011009757A2 publication Critical patent/WO2011009757A2/fr
Publication of WO2011009757A3 publication Critical patent/WO2011009757A3/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/14—Drugs for dermatological disorders for baldness or alopecia

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Dermatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Cosmetics (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

L'invention concerne l'utilisation d'au moins une bêta-défensine humaine, de ses analogues ou agents actifs pouvant stimuler une expression de la bêta-défensine humaine, pour influencer le processus de pigmentation naturel de la peau et/ou des phanères.
PCT/EP2010/060026 2009-07-23 2010-07-13 Utilisation de bêta-défensine humaine pour influencer le processus de pigmentation naturel WO2011009757A2 (fr)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
DE102009027953.9 2009-07-23
DE102009027953 2009-07-23
DE102009044970A DE102009044970A1 (de) 2009-07-23 2009-09-24 Verwendung von humanem beta-Defensin zur Beeinflussung des natürlichen Pigmentierungsprozesses
DE102009044970.1 2009-09-24

Publications (2)

Publication Number Publication Date
WO2011009757A2 WO2011009757A2 (fr) 2011-01-27
WO2011009757A3 true WO2011009757A3 (fr) 2011-03-31

Family

ID=43384052

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2010/060026 WO2011009757A2 (fr) 2009-07-23 2010-07-13 Utilisation de bêta-défensine humaine pour influencer le processus de pigmentation naturel

Country Status (2)

Country Link
DE (1) DE102009044970A1 (fr)
WO (1) WO2011009757A2 (fr)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE102009044970A1 (de) 2009-07-23 2011-01-27 Henkel Ag & Co. Kgaa Verwendung von humanem beta-Defensin zur Beeinflussung des natürlichen Pigmentierungsprozesses
EP3120850B1 (fr) * 2012-12-14 2018-11-07 Unilever N.V. Niacinamide pour induire la production de peptides antimicrobiens
WO2015195677A1 (fr) * 2014-06-18 2015-12-23 Medicell Technologies, Llc Compositions stimulant les cellules souches et procédés
RS63786B1 (sr) 2015-12-15 2022-12-30 Medicell Technologies Llc Kompozicije za stimulisanje matičnih ćelija i postupci za lečenje melazme

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006103037A2 (fr) * 2005-03-29 2006-10-05 Henkel Kommanditgesellschaft Auf Aktien Composition contenant la $g(b)-defensine 2
WO2008028779A1 (fr) * 2006-09-06 2008-03-13 Henkel Ag & Co. Kgaa Procédé de caractérisation moléculaire de cheveux âgés

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3725030A1 (de) 1987-07-29 1989-02-09 Henkel Kgaa Oberflaechenaktive hydroxysulfonate
US5136093A (en) 1991-02-06 1992-08-04 Smith Ronald J Quaternized panthenol compounds and their use
DE4413686C2 (de) 1994-04-20 1996-10-24 Henkel Kgaa Kationische Zuckertenside, Verfahren zu ihrer Herstellung und deren Verwendung
FR2843125B1 (fr) 2002-08-02 2012-11-16 Coletica Principes actifs stimulant les beta-defensives humaines de type 2 et/ou de type 3, et compositions cosmetiques ou pharmaceutiques comprenant de tels principes actifs
DE102009044970A1 (de) 2009-07-23 2011-01-27 Henkel Ag & Co. Kgaa Verwendung von humanem beta-Defensin zur Beeinflussung des natürlichen Pigmentierungsprozesses

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006103037A2 (fr) * 2005-03-29 2006-10-05 Henkel Kommanditgesellschaft Auf Aktien Composition contenant la $g(b)-defensine 2
WO2008028779A1 (fr) * 2006-09-06 2008-03-13 Henkel Ag & Co. Kgaa Procédé de caractérisation moléculaire de cheveux âgés

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
CANDILLE SOPHIE I ET AL: "A -defensin mutation causes black coat color in domestic dogs.", SCIENCE (NEW YORK, N.Y.) 30 NOV 2007 LNKD- PUBMED:17947548, vol. 318, no. 5855, 30 November 2007 (2007-11-30), pages 1418 - 1423, XP002610513, ISSN: 1095-9203 *

Also Published As

Publication number Publication date
DE102009044970A1 (de) 2011-01-27
WO2011009757A2 (fr) 2011-01-27

Similar Documents

Publication Publication Date Title
WO2011009759A3 (fr) Utilisation de dihydroquercétine et d'au moins un acide aminé pour influencer positivement le processus de pigmentation naturel
PL2640352T3 (pl) Hydrolizat kolagenu do zastosowania do poprawy zdrowia ludzkiej skóry, włosów i/lub paznokci
ZA201304638B (en) Composition for use in the prevention and /or treatment of skin condition and skin diseases.
HK1162540A1 (en) Peptides for use in cosmetic or pharmaceutical treatment of the skin, mucous membranes and/or scalp //
ZA201202705B (en) Peptides used in the treatment and/or care of the skin.mucous membranes and/or hair and its use in cosmetic or pharmaceutical compositions
FR2969495B1 (fr) Extrait de parties aeriennes de maca riche en polyphenols et composition le comprenant
IL219318A (en) 3,5- Dimethoxy-4'-Hydroxystylbenzene (pter) for use in the treatment of diseases, damages or skin injuries and the process of preparing it
MX2018004616A (es) Cosmetica qie tiene bacterias probioticas.
EP4272839A3 (fr) Traitement de la rhinite allergique à l'aide d'une association de mométasone et d'olopatadine
TN2015000520A1 (en) Pharmaceutical compositions comprising collagen and sodium hyaluronate
IL212567A (en) Zaxanthin, alone or in combination with rutin, spermidine, or both, for the treatment of scalp disorders, use of zaxanthin, alone or in combination with rutin, spermidine or both, for the preparation of a medicinal or cosmetic or nutritional preparation for the treatment of scalp, and a medicinal, cosmetic or nutritional preparation containing Alone or in a mixture with routine, spermidine, or both
EP2274411A4 (fr) Compositions de xanthohumol et procédés de traitement des maladies ou des affections cutanées
WO2015084883A3 (fr) Compositions et méthodes pour traiter l'arthrose
EP2537513A3 (fr) Utilisation d'extrait d'Anogeissus pour la production de fibrilline dans la peau
HK1124779A1 (en) Use of an unsaponifiable extract of plant pulp in the treatment of skin ageing
WO2011009757A3 (fr) Utilisation de bêta-défensine humaine pour influencer le processus de pigmentation naturel
WO2011009758A3 (fr) Utilisation de purine et/ou d'un dérivé de purine et d'au moins un oligonucléotide pour influencer le processus de pigmentation naturel
WO2011009763A3 (fr) Agent cosmétique contenant de la purine et/ou un dérivé de purine et du sclaréol
WO2011035945A3 (fr) Utilisation d'une association de carnitine et/ou d'un dérivé de la carnitine et de purine et/ou d'un dérivé de la purine pour influer sur le processus naturel de pigmentation
WO2014045065A3 (fr) Compositions diététiques et leurs utilisations
WO2011009761A3 (fr) Utilisation de carnitine et de dihydroquercétine pour influencer positivement le processus de pigmentation naturel
ZA201804198B (en) Composition of olivetol and method of use reduce or inhibit the effects of tetrahydrocannabinol in the human body
EP2404611A4 (fr) Peptide pour le traitement prophylactique ou thérapeutique de tumeurs de la peau, dans les stades initiaux
PT2509944E (pt) Novos derivados do peróxido, seus processos de preparação e sua utilização em medicina humana e nos cosméticos para tratamento ou prevenção da acne
EP2902024A4 (fr) Composition synergique de nitazoxanide et de mébendazole, procédés de préparation correspondants et utilisation de cette composition dans le traitement de la parasitose humaine

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 10731524

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 10731524

Country of ref document: EP

Kind code of ref document: A2